Madison-based Exact Sciences Corp. beat Wall Street analysts’ revenue and earnings per share projections Tuesday, with numbers on target to what the health diagnostics company anticipated earlier this year.
Exact Sciences, the maker of Cologuard, the take-home colon cancer test, reported fourth quarter revenue of $295.6 million, above the $294.6 million projected by Zacks. The company reported quarterly income of $77.9 million, or 54 cents per diluted share, which also beat projections. Zachs was expecting a quarterly loss of 34 cents per share.
The company’s stock (Nasdaq: EXAS) was down roughly two points in after-hours trading Tuesday to $92.72 per share.
“The Exact Sciences team delivered another strong quarter to end a transformative year for the company,” said Kevin Conroy, chairman and CEO of Exact Sciences, in a statement. “The strong foundation we’ve built for Cologuard and Oncotype DX and the capabilities of our combined team position us well to continue to grow our core business and deliver more innovative cancer tests to people in need.”